The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/100 - 1/500. Detects a band of approximately 102 kDa (predicted molecular weight: 102 kDa).
1/50 - 1/100.
Predominant hexokinase isozyme expressed in insulin-responsive tissues such as skeletal muscle.
Carbohydrate metabolism; hexose metabolism.
Belongs to the hexokinase family. Contains 2 hexokinase domains.
The N- and C-terminal halves of this hexokinase show extensive sequence similarity to each other. The catalytic activity is associated with the C-terminus while regulatory function is associated with the N-terminus. Each domain can bind a single glucose and Gluc-6-P molecule.
Mitochondrion outer membrane. Its hydrophobic N-terminal sequence may be involved in membrane binding.
Western blot - Anti-Hexokinase II antibody (ab37593)
Anti-Hexokinase II antibody (ab37593) at 1/500 dilution + A375 cell lysate
Predicted band size: 102 kDa Observed band size: 102 kDa Additional bands at: 30 kDa, 40 kDa, 60 kDa, 75 kDa. We are unsure as to the identity of these extra bands.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Hexokinase II antibody (ab37593)This image is courtesy of an anonymous Abreview
ab37593 staining Hexokinase II in Human renal cancer tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 1% serum for 20 minutes; antigen retrieval was by heat mediation in a citrate buffer. Samples were incubated with primary antibody (1/200) for 45 minutes at 22°C. A Biotin-conjugated Goat anti-rabbit IgG polyclonal (1/400) was used as the secondary antibody.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Hexokinase II antibody (ab37593)
ab37593, at 1/100 dilution, staining human hepatocarcinoma tissue by immunohistochemistry.
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining.